Dose Reduction versus Dose-interval Prolongation in Eribulin Mesilate Monotherapy in Patients with Metastatic Breast Cancer: A Retrospective Comparative Study

• Published in: YAKUGAKU ZASSHI Vol. 136; no. 7; pp. 1023 - 1029
• Main Authors: Sasaki, Toshinori, Oshima, Yumiko, Mishima, Etsuko, Ban, Akiko, Katsuragawa, Kenji, Nagamatsu, Hidetsugu, Yoshioka, Yuki, Tsukiyama, Ikuto, Hisada, Tatsuya, Itakura, Yukari, Mizutani, Mitsuhiro
• Format: Journal Article
• Language: Japanese
• Published: Japan The Pharmaceutical Society of Japan 01.07.2016
• Subjects: Adult; Aged; Breast Neoplasms - drug therapy; Breast Neoplasms - mortality; dose adjustment; Drug Administration Schedule; Endpoint Determination; eribulin mesilate; Female; Furans - administration & dosage; Furans - adverse effects; Humans; Ketones - administration & dosage; Ketones - adverse effects; metastatic breast cancer; Middle Aged; Neoplasm Recurrence, Local; Peripheral Nervous System Diseases - chemically induced; Peripheral Nervous System Diseases - epidemiology; relative dose intensity; Retrospective Studies; Survival Rate; Treatment Failure; Treatment Outcome

It is often necessary to modify the dose or schedule of eribulin mesilate (Eri) because of adverse events. Therefore, we retrospectively investigated the optimal approach for Eri dose adjustment and/or dosage interval adjustment. Patients who received Eri at the institutions affiliated with the Divi...